Antifungal use in intensive care units: another uncertainty that highlights the need for precision medicine

Epidemiologic data have shown an increasing prevalence of candidemia in non-immunocompromised critically ill patients (1). Candida is the fourth most common organism causing bloodstream infections in hospitals, accounting for 10% of all bloodstream infections with an attributable mortality ranging from 42% to 63% (2-6) leading to increased intensive care unit (ICU) and hospital stay (7,8). In some studies one half to two-thirds of all episodes of candidemia are acquired in ICUs (2-6)